Summary
Although (−)-deprenyl is known to be metabolized to methamphetamine and amphetamine, two small-scale double-blind trials indicate that neither metabolite contributes to the therapeutic benefit conferred by this drug in certain patients with Parkinson's disease: the manipulation of urinary pH, which alters the rate of excretion of these metabolites, failed to change the response pattern; substitution of a metabolite mixture for active drug caused a falling off in benefit.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beckett, A. H., Rowland, M.: Urinary excretion kinetics of amphetamine in man. J. Pharm. Pharmacol.17, 628–639 (1965 a).
Beckett, A. H., Rowland, M.: Urinary excretion kinetics of methylamphetamine in man. J. Pharm. Pharmacol.17, 1095–1145 (1965 b).
Birkmayer, W., Riederer, P., Youdim, M. B. H., Linauer, W.: The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of Mao-B, deprenil. J. Neural Transm.36, 303–326 (1975).
Bond, A., Lader, M.: The use of analogue scales in rating subjective feelings. Br. J. Med. Psychol.47, 211–218 (1974).
Canter, G. J., de la Torre, R., Mier, M.: A method for evaluating disability in patients with Parkinson's disease. J. Nerv. Ment. Dis.133, 143–147 (1961).
Duvoisin, R. C.: The evaluation of extrapyramidal disease. In: Monoamines Noyaux Gris Centraux et Syndrome de Parkinson (de Ajuriaguerra, J., Gauthier, G., eds.), pp. 313–325. Geneva: Georg. 1971.
Elsworth, J. D., Glover, V., Reynolds, G. P., Sandier, M., Lees, A. J., Phuapradit, P., Shaw, K., Stern, G. M., Kumar, P.: Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacology57, 33–38 (1978).
Glover, V., Elsworth, J. D., Sandler, M.: Dopamine oxidation and its inhibition by (−)-deprenyl in man. J. Neural Transm., Suppl. 16, pp. 163–172. Wien-New York: Springer. 1980.
Knoll, J.: Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Monoamine Oxidase and its Inhibition, Ciba Foundation Symposium 39 (Wolstenholme, G. E. W., Knight, J., eds.), pp. 135–161. Amsterdam: Elsevier. 1976.
Knoll, J.: The possible mechanisms of action of (−)-deprenyl in Parkinson's disease. J. Neural Transm.43, 177–198 (1978).
Knoll, J., Ecsery, Z., Magyar, K., Satory, E.: Novel deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action. Biochem. Pharmacol.27, 1739–1747 (1978).
Knoll, J., Magyar, K.: Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Monoamine Oxidase—New Vistas. Adv. Biochem. Psychopharmacol., Vol. 5 (Costa, E., Sandler, M., eds.), pp. 393–408. New York: Raven Press. 1972.
Lees, A. J., Shaw, K., Kohout, L. J., Stern, G. M., Elsworth, J. D., Sandler, M., Youdim, M. B. H.: Deprenyl in Parkinson's disease. Lancetii, 791–796 (1977).
Lipper, S., Murphy, D. L., Slater, S., Buchsbaum, M. S.: Comparative behavioral effects of clorgyline and pargyline in man: a preliminary study. Psychopharmacology62, 123–128 (1979).
Mann, J., Gershon, S.: L-Deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci.26, 877–882 (1980).
Parkes, J. D., Tarsy, D., Marsden, C. D., Bovill, K. T., Phipps, J. A., Rose, P., Asselman, P.: Amphetamines in the treatment of Parkinson's disease. J. Neurol. Neurosurg. Psychiat.38, 232–237 (1975).
Pycock, C., Glover V., Sandler, M.: In preparation (1982).
Reynolds, G. P., Elsworth, J. D., Blau, K., Sandler, M., Lees, A. J., Stern, G. M.: Deprenyl is metabolized to methamphetamine and amphetamine in man. Br. J. Clin. Pharmac.6, 542–544 (1978).
Sandler, M., Glover, V., Ashford, A., Esmail, A.: The inhibition of tyramine oxidation and the tyramine hypertensive response (“cheese effect”) may be independent phenomena. J. Neural Transm.48, 241–247 (1980).
Stern, G. M., Lees, A. J., Sandler, M.: Recent observations on the clinical pharmacology of (−)-deprenyl. J. Neural Transm.43, 245–251 (1978).
Tringer, L., Haits, G., Varga, E.: The effect of (−)-phenyl-isopropyl-methyl-propinylamine-HCl in depressions. In: Proc. Vth Conf. Hung. Ther. Invest. Pharmacol., Soc. Pharmacol. Hung. (Leszkovszky, G. P., ed.), pp. 111–114. Budapest: Hungarian Academy of Sciences. 1968.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Elsworth, J.D., Sandler, M., Lees, A.J. et al. The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties. J. Neural Transmission 54, 105–110 (1982). https://doi.org/10.1007/BF01249283
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01249283